Price Reaps Windfall From Selling Off Stocks At Center Of Ethics Controversy
HHS Secretary Tom Price, before he was confirmed, pledged to divest his shares in Innate Immunotherapeutics. Meanwhile, a look at what questions FDA nominee Scott Gottlieb will face at his hearing this week.
ProPublica:
Tom Price’s $150,000-Plus Stock Windfall
Tom Price doesn’t appear to have suffered a financial hit when he fulfilled his pledge to sell off some assets as the new head of the Department of Health and Human Services. On one transaction alone, Price made a profit of more than $150,000 on shares he held in a tiny Australian biotech company, according to his financial disclosures. His purchases of that stock, which came while he was serving in Congress, were the subject of particular scrutiny during his confirmation hearings in January. He was one of a handful of U.S. investors allowed to buy discounted shares in Innate Immunotherapeutics, which was working on an experimental multiple sclerosis drug. (Faturechi, 4/3)
CQ Roll Call:
FDA Nominee's Vast Public Record Hints At Views On Major Issues
Scott Gottlieb, the Trump administration's choice to lead the Food and Drug Administration, will likely face questions during a confirmation hearing Wednesday about his potential for conflicts of interest and the details of his well-documented views on issues the agency oversees. Gottlieb was a deputy commissioner at the FDA during the administration of George W. Bush. Since leaving the agency a decade ago, he has been a practicing physician who also made millions of dollars advising pharmaceutical companies. (Siddons, 4/3)
